AllianceBernstein’s Intellia Therapeutics NTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $927K | Hold |
103,100
| – | – | ﹤0.01% | 2373 |
|
|
2025
Q4 | $927K | Hold |
103,100
| – | – | ﹤0.01% | 2381 |
|
|
2025
Q3 | $1.78M | Hold |
103,100
| – | – | ﹤0.01% | 2069 |
|
|
2025
Q2 | $967K | Hold |
103,100
| – | – | ﹤0.01% | 2306 |
|
|
2025
Q1 | $733K | Sell |
103,100
-162,218
| -61% | -$1.64M | ﹤0.01% | 2388 |
|
|
2024
Q4 | $3.09M | Sell |
265,318
-1,928,469
| -88% | -$30.1M | ﹤0.01% | 1734 |
|
|
2024
Q3 | $45.1M | Buy |
2,193,787
+410,903
| +23% | +$9.47M | 0.02% | 632 |
|
|
2024
Q2 | $39.9M | Buy |
1,782,884
+211,360
| +13% | +$5.03M | 0.01% | 664 |
|
|
2024
Q1 | $43.2M | Sell |
1,571,524
-92,218
| -6% | -$2.56M | 0.02% | 649 |
|
|
2023
Q4 | $50.7M | Buy |
1,663,742
+116,630
| +8% | +$3.35M | 0.02% | 577 |
|
|
2023
Q3 | $48.9M | Sell |
1,547,112
-175,665
| -10% | -$6.82M | 0.02% | 562 |
|
|
2023
Q2 | $70.3M | Sell |
1,722,777
-42,151
| -2% | -$1.71M | 0.03% | 482 |
|
|
2023
Q1 | $65.8M | Buy |
1,764,928
+75,206
| +4% | +$2.95M | 0.03% | 488 |
|
|
2022
Q4 | $59M | Buy |
1,689,722
+267,521
| +19% | +$12.7M | 0.03% | 525 |
|
|
2022
Q3 | $79.6M | Sell |
1,422,201
-282,450
| -17% | -$17.5M | 0.04% | 419 |
|
|
2022
Q2 | $88.2M | Sell |
1,704,651
-43,030
| -2% | -$2.19M | 0.04% | 411 |
|
|
2022
Q1 | $127M | Buy |
1,747,681
+285,021
| +19% | +$24.1M | 0.05% | 337 |
|
|
2021
Q4 | $173M | Buy |
1,462,660
+225,756
| +18% | +$28.3M | 0.06% | 291 |
|
|
2021
Q3 | $166M | Buy |
1,236,904
+27,436
| +2% | +$4.15M | 0.07% | 275 |
|
|
2021
Q2 | $196M | Sell |
1,209,468
-548,344
| -31% | -$42.7M | 0.08% | 238 |
|
|
2021
Q1 | $141M | Buy |
1,757,812
+1,695,712
| +2,731% | +$114M | 0.06% | 300 |
|
|
2020
Q4 | $3.38M | Buy |
62,100
+500
| +0.8% | +$18.2K | ﹤0.01% | 1708 |
|
|
2020
Q3 | $1.23M | Sell |
61,600
-1,300
| -2% | -$27.1K | ﹤0.01% | 2095 |
|
|
2020
Q2 | $1.32M | Buy |
62,900
+9,300
| +17% | +$158K | ﹤0.01% | 2062 |
|
|
2020
Q1 | $656K | Hold |
53,600
| – | – | ﹤0.01% | 2225 |
|
|
2019
Q4 | $786K | Hold |
53,600
| – | – | ﹤0.01% | 2372 |
|
|
2019
Q3 | $716K | Hold |
53,600
| – | – | ﹤0.01% | 2392 |
|
|
2019
Q2 | $877K | Hold |
53,600
| – | – | ﹤0.01% | 2370 |
|
|
2019
Q1 | $915K | Sell |
53,600
-5,200
| -9% | -$77.5K | ﹤0.01% | 2279 |
|
|
2018
Q4 | $803K | Hold |
58,800
| – | – | ﹤0.01% | 2294 |
|
|
2018
Q3 | $1.68M | Hold |
58,800
| – | – | ﹤0.01% | 2067 |
|
|
2018
Q2 | $1.61M | Buy |
58,800
+35,400
| +151% | +$858K | ﹤0.01% | 2073 |
|
|
2018
Q1 | $494K | Sell |
23,400
-4,900
| -17% | -$121K | ﹤0.01% | 2521 |
|
|
2017
Q4 | $544K | Buy |
28,300
+1,200
| +4% | +$27.7K | ﹤0.01% | 2504 |
|
|
2017
Q3 | $673K | Sell |
27,100
-3,300
| -11% | -$62.2K | ﹤0.01% | 2468 |
|
|
2017
Q2 | $486K | Buy |
30,400
+4,600
| +18% | +$64.3K | ﹤0.01% | 2630 |
|
|
2017
Q1 | $364K | Hold |
25,800
| – | – | ﹤0.01% | 2631 |
|
|
2016
Q4 | $338K | Buy |
25,800
+2,900
| +13% | +$43.6K | ﹤0.01% | 2694 |
|
|
2016
Q3 | $390K | Buy |
22,900
+2,600
| +13% | +$50.3K | ﹤0.01% | 2616 |
|
|
2016
Q2 | $433K | Buy |
+20,300
| New | +$540K | ﹤0.01% | 2565 |
|
Other funds holding NTLA
AIM
VPM
VCM
RP
AllianceBernstein's NTLA Position: Q1 2026 in Review
AllianceBernstein held its Intellia Therapeutics (NTLA) position steady in Q1 2026 at 103,100 shares worth $927K. The position accounts for ﹤0.01% of the portfolio, ranked #2373.
AllianceBernstein first reported a position in NTLA in Q2 2016 and has held it in 40 quarters since. The position peaked at $196M in Q2 2021. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.
- AllianceBernstein held 103,100 shares of Intellia Therapeutics worth $927K as of Q1 2026.
- AllianceBernstein left its Intellia Therapeutics share count unchanged in Q1 2026.
- Intellia Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q1 2026, its #2373 holding.
- AllianceBernstein first reported a position in Intellia Therapeutics in Q2 2016 and has held it in 40 quarters since.
- AllianceBernstein's Intellia Therapeutics position peaked at $196M in Q2 2021.
- 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.
Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.